Guselkumab Leads Efficacy Rankings in Crohn’s Disease Indirect Comparisons
A new network meta-analysis of advanced therapies for Crohn’s disease places guselkumab at the top of the efficacy hierarchy during both induction and maintenance, while stopping short of claiming true superiority over competing biologics and small molecules. The analysis pooled 27 phase 3 randomized controlled trials and compared approved agents across a broad treatment network that included adalimumab, infliximab, vedolizumab, ustekinumab, risankizumab, upadacitinib, mirikizumab, and guselkumab.
The signal is real, but it is not simple.
At induction, guselkumab 400 mg achieved the highest P-scores for both clinical response and clinical remission, and its odds of reaching those endpoints were higher than placebo and several active comparators. Mirikizumab also separated from placebo, yet its position in the treatment hierarchy sat in the middle rather than at the top. In practical terms, the analysis suggests that blockade of the IL-23 pathway may deliver a stronger short-term anti-inflammatory effect than some older biologic strategies, particularly when the target is rapid control of mucosal and systemic intestinal inflammation.
Induction Therapy Put IL-23 Targeting Ahead of Several Comparators
The induction findings deserve attention because they reflect the period when patients and clinicians are deciding whether a therapy can meaningfully quiet an active flare. Crohn’s disease is driven by immune activation in the gut wall, and agents that interrupt IL-23 signaling can plausibly blunt the inflammatory cascade that sustains ulceration, pain, diarrhea, and biomarker elevation. Guselkumab’s top ranking in this setting suggests that this mechanism may translate into measurable clinical benefit across trial populations.
Mirikizumab followed a more modest pattern. It outperformed placebo, yet the evidence base for its node was narrow, with the network informed by a single eligible phase 3 study. One trial can establish efficacy, but it cannot fully define how a drug behaves across different disease burdens, background therapies, or patient phenotypes. In a disease as heterogeneous as Crohn’s, that limitation carries weight.
Maintenance Rankings Favored Guselkumab, but the Gaps Were Narrow
During maintenance therapy, guselkumab 200 mg and 100 mg again occupied the highest rankings for clinical response and remission. Even so, the direct meaning of those ranks is restrained by the structure of the evidence. Differences between guselkumab and several active comparators did not reach statistical significance, and the comparisons rested predominantly on indirect evidence.
Maintenance trials in Crohn’s disease often involve a more selected population than induction studies because only initial responders move forward. That enrichment can make a treatment look stronger than it would in an unselected clinic population, especially when placebo responders and early nonresponders are filtered out before the maintenance phase. Trial design, prior biologic exposure, baseline disease severity, and outcome definitions all shape the apparent ranking. In this network, those differences were substantial enough that the ranking table should be read as a signal of relative performance, not as a verdict on one drug replacing another.
Safety Comparisons Showed No Clear Winner
Across the network, no consistent evidence emerged for major safety differences between interventions. Serious adverse events and serious infections were examined, and guselkumab achieved favorable rankings in those categories, yet few statistically significant differences separated active therapies. The safety networks were also limited by heterogeneity and inconsistency, which reduced confidence in any clean between-drug comparison.
The safety picture matters because advanced Crohn’s therapies often trade one kind of clinical burden for another. Biologics and small molecules can reduce intestinal inflammation, but they also require careful attention to infection risk, laboratory monitoring, and the cumulative consequences of immunomodulation. A treatment that ranks well on efficacy but poorly on safety may be difficult to justify in a patient with recurrent infections, frailty, or complex comorbidity. In this analysis, no such decisive separation appeared.
What the Network Meta-Analysis Can and Cannot Prove
The strength of a network meta-analysis lies in its ability to place therapies on a shared comparative grid when head-to-head trials are scarce. The weakness is equally important: indirect comparisons depend on assumptions that the underlying studies are sufficiently similar in patient selection, disease severity, endpoint timing, and trial conduct. When those assumptions break down, the ranking can drift away from clinical reality.
This review followed PRISMA-NMA, the Cochrane Handbook, and ISPOR guidance, and it searched MEDLINE, EMBASE, and the Cochrane Library from inception to June 2026. Even with that rigorous framework, the authors had to work with a body of phase 3 evidence that was uneven across agents. Some drugs were represented across multiple trials, while others entered the network through a narrower evidence base. That imbalance shaped the certainty around the rankings, especially for maintenance therapy.
For clinicians, the practical message is straightforward: guselkumab emerged as the highest-ranked option in this indirect evidence set, but the analysis does not establish definitive superiority. The same caution applies to mirikizumab, whose efficacy signal was favorable but rested on a thinner evidentiary foundation.
Crohn’s Disease Care Still Needs Direct Head-to-Head Evidence
In a disease marked by relapsing inflammation, treatment selection rarely hinges on one meta-analytic ranking alone. Patients arrive with different degrees of bowel inflammation, prior anti-TNF exposure, steroid dependence, fistulizing disease, and tolerance for ongoing monitoring. A drug that looks strongest in a pooled indirect comparison may still be a second-choice option for a patient whose history makes another mechanism more attractive.
The biologic logic behind IL-23 inhibition remains compelling. By dampening a pathway central to T-cell–mediated intestinal inflammation, these agents can plausibly shift patients from active disease toward clinical response and remission. What remains unresolved is how that promise should be weighed against other approved therapies in the absence of robust direct comparison trials. The current network suggests a hierarchy, but the hierarchy is provisional.
The most actionable conclusion from this analysis is also the most restrained: guselkumab ranked highest across several efficacy outcomes, yet the findings are shaped by indirect evidence, methodological heterogeneity, and limited safety certainty. In Crohn’s disease, that is enough to inform discussion, not enough to settle the question.